Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.66 |
| ▸ | CHRNA5 | P30532 | 4/20 | 0.66 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | CA9 | Q16790 | 2/20 | 0.63 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60783 | 0.95 | SMN1; SMN2 (0.67) | KMONPC1RAB9AL3MBTL1CHRNB2 | |
| SCHEMBL4456727 | 0.89 | CA9 (0.55) | KMONPC1RAB9AL3MBTL1CHRNB2 | |
| SCHEMBL4456725 | 0.89 | CA9 (0.55) | KMONPC1RAB9AL3MBTL1CHRNB2 | |
| SCHEMBL1422760 | 0.88 | CA9 (0.65) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL1422479 | 0.88 | CHRNB2 (0.64) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL12171569 | 0.86 | NPC1 (0.76) | KMONPC1RAB9AL3MBTL1TP53 | |
| SCHEMBL28784577 | 0.85 | S1PR1 (0.62) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL12171589 | 0.83 | SMN1; SMN2 (0.75) | NPC1RAB9ACHRNB2CHRNA5CHRNA4 | |
| SCHEMBL61063 | 0.83 | NPC1 (0.69) | KMONPC1RAB9AL3MBTL1TP53 | |
| SCHEMBL60427 | 0.83 | NPC1 (0.76) | KMONPC1RAB9AL3MBTL1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | claimed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| EP-2226074-B1 | Pharmaceutical compositions and their methods of use | ABBVIE INC (US) | 2015-11-04 | — | — | EP | claimed |
| EP-2101763-B1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LAB (US) | 2012-07-18 | — | — | EP | claimed |
| EP-2226074-A2 | Pharmaceutical compositions and their methods of use | Abbott Laboratories (US) | 2010-09-08 | — | — | EP | claimed |
| CN-101605542-A | Pharmaceutical compositions and methods of use thereof | ABBOTT LAB (US) | 2009-12-16 | — | — | CN | claimed |
| EP-2101763-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-09-23 | — | — | EP | claimed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | claimed |
| WO-2008073942-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | claimed |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBVIE INC (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2974727-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9186407-B2 | Pharmaceutical compositions and their methods of use | ABBVIE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2226074-B1 | Pharmaceutical compositions and their methods of use | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9040568-B2 | Pharmaceutical compositions for the treatment of pain | ABBVIE INC. (US) | 2015-05-26 | — | — | US | disclosed |
| CN-101605542-A | Pharmaceutical compositions and methods of use thereof | ABBOTT LAB (US) | 2009-12-16 | — | — | CN | disclosed |
| WO-2009148452-A1 | NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-2101763-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073942-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269236-A1 | Novel 1,2,4 Oxadiazole Compounds and Methods of Use Thereof | OXA1L, CYP11B2, CYP1B1 | KMO 213/4885NPC1 1201/4885RAB9A 4444/4885 |
| US-20080167286-A1 | Pharmaceutical compositions and their methods of use | CHRNA4, CHRNB4, CHRNA5 | KMO 2666/4885NPC1 1677/4885RAB9A 1978/4885 |
| US-20160022658-A1 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | CHRNA4, CHRNB4, CHRNA5 | KMO 2666/4885NPC1 1677/4885RAB9A 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.